Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.60 |
| ▸ | PTGER2 | P43116 | 14/20 | 0.60 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082484 | 0.91 | PTGER4 (0.68) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4077429 | 0.89 | PTGER4 (0.69) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4082462 | 0.87 | PTGER4 (0.62) | PTGER4PTGER2PTGER3CTSDBACE1 | |
| SCHEMBL4086039 | 0.86 | PTGER4 (0.42) | PTGER4PTGER2CYP1A2CYP2C19CTSD | |
| SCHEMBL4082519 | 0.85 | PTGER4 (0.76) | PTGER4PTGER2PTGER3CTSDBACE1 | |
| SCHEMBL4077760 | 0.83 | PTGER4 (0.82) | PTGER4PTGER2 | |
| SCHEMBL4081976 | 0.81 | PTGER4 (0.72) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4077231 | 0.80 | PTGER4 (0.61) | PTGER4PTGER2PTGER3CYP1A2CTSD | |
| SCHEMBL4080468 | 0.80 | PTGER4 (0.60) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4077399 | 0.80 | PTGER4 (0.60) | PTGER4PTGER2PTGER3CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER4 33/4885PTGER2 39/4885PTGER3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.